Detalhe da pesquisa
1.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369086
2.
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180218
3.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Mult Scler
; 28(12): 1944-1962, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35765217
4.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947619
5.
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler
; 25(9): 1255-1262, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043658
6.
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Mult Scler J Exp Transl Clin
; 9(1): 20552173221142741, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36619856
7.
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Mult Scler Relat Disord
; 57: 103385, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158476
8.
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
JAMA Neurol
; 78(5): 558-567, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33779698
9.
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
Mult Scler Relat Disord
; 53: 103012, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34116480